These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32676325)

  • 21. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.
    Wang X; Kong C; Xu W; Yang S; Shi D; Zhang J; Du M; Wang S; Bai Y; Zhang T; Chen Z; Ma Z; Wang J; Dong G; Sun M; Yin R; Chen F
    Thorac Cancer; 2019 Oct; 10(10):1904-1912. PubMed ID: 31414580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ryanodine receptor (
    Wang Y; Chen Y; Zhang L; Xiong J; Xu L; Cheng C; Xu Z
    Transl Cancer Res; 2022 Jul; 11(7):2070-2083. PubMed ID: 35966320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding the Impact of Population and Cancer Type on Tumor Mutation Burden Scores: A Comprehensive Whole-Exome Study in Cancer Patients From India.
    Tanwar NA; Malhotra R; Satheesh AP; Khuntia SP; Sreekanthreddy P; Varghese L; Kolla S; Chandrani P; Choughule A; Pange P; Gupta V; Noronha V; Patil VM; Pramanik R; Kumar S; Nayak SP; Babu S; Shetty R; Kantharaju M; Chinder PS; Korlimarla A; Srinath BS; Prabhash K; Rishi KD; Goswami HM; Veldore VH
    JCO Glob Oncol; 2023 Sep; 9():e2300047. PubMed ID: 38085046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Profiling of 520 Candidate Genes in 50 Surgically Treated Chinese Small Cell Lung Cancer Patients.
    Yuan T; Wang X; Sun S; Cao Z; Feng X; Gao Y
    Front Oncol; 2021; 11():644434. PubMed ID: 34168983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of
    Jia M; Yao L; Yang Q; Chi T
    Front Oncol; 2020; 10():168. PubMed ID: 32154170
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Wang L; Yan K; He X; Zhu H; Song J; Chen S; Cai S; Zhao Y; Wang L
    J Cancer; 2021; 12(1):217-223. PubMed ID: 33391418
    [No Abstract]   [Full Text] [Related]  

  • 28. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.
    Stenzinger A; Endris V; Budczies J; Merkelbach-Bruse S; Kazdal D; Dietmaier W; Pfarr N; Siebolts U; Hummel M; Herold S; Andreas J; Zoche M; Tögel L; Rempel E; Maas J; Merino D; Stewart M; Zaoui K; Schlesner M; Glimm H; Fröhling S; Allen J; Horst D; Baretton G; Wickenhauser C; Tiemann M; Evert M; Moch H; Kirchner T; Büttner R; Schirmacher P; Jung A; Haller F; Weichert W; Dietel M
    J Thorac Oncol; 2020 Jul; 15(7):1177-1189. PubMed ID: 32119917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in
    Li T; Pang X; Wang J; Wang S; Guo Y; He N; Xing P; Li J
    Front Oncol; 2021; 11():591922. PubMed ID: 34136375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with
    Offin M; Rizvi H; Tenet M; Ni A; Sanchez-Vega F; Li BT; Drilon A; Kris MG; Rudin CM; Schultz N; Arcila ME; Ladanyi M; Riely GJ; Yu H; Hellmann MD
    Clin Cancer Res; 2019 Feb; 25(3):1063-1069. PubMed ID: 30045933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations.
    Zhang Y; Ma Y; Li Y; Shen X; Yu Y; Pan Y; Zhang Y; Zheng D; Zhao Y; Ye T; Li B; Hu H; Sun Y; Zhang Y; Xiang J; Chen H
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):747-757. PubMed ID: 30673871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay.
    Chaudhary R; Quagliata L; Martin JP; Alborelli I; Cyanam D; Mittal V; Tom W; Au-Young J; Sadis S; Hyland F
    Transl Lung Cancer Res; 2018 Dec; 7(6):616-630. PubMed ID: 30505706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
    Chalmers ZR; Connelly CF; Fabrizio D; Gay L; Ali SM; Ennis R; Schrock A; Campbell B; Shlien A; Chmielecki J; Huang F; He Y; Sun J; Tabori U; Kennedy M; Lieber DS; Roels S; White J; Otto GA; Ross JS; Garraway L; Miller VA; Stephens PJ; Frampton GM
    Genome Med; 2017 Apr; 9(1):34. PubMed ID: 28420421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
    Zhang C; Li Z; Qi F; Hu X; Luo J
    Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of tumor mutation burden calculation from gene panel sequencing data.
    Xu Z; Dai J; Wang D; Lu H; Dai H; Ye H; Gu J; Chen S; Huang B
    Onco Targets Ther; 2019; 12():3401-3409. PubMed ID: 31123404
    [No Abstract]   [Full Text] [Related]  

  • 36. Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors.
    Wen Y; Lin A; Zhu W; Wei T; Luo P; Guo L; Zhang J
    Front Pharmacol; 2021; 12():645862. PubMed ID: 34163353
    [No Abstract]   [Full Text] [Related]  

  • 37. Predicting Tumor Mutational Burden From Lung Adenocarcinoma Histopathological Images Using Deep Learning.
    Niu Y; Wang L; Zhang X; Han Y; Yang C; Bai H; Huang K; Ren C; Tian G; Yin S; Zhao Y; Wang Y; Shi X; Zhang M
    Front Oncol; 2022; 12():927426. PubMed ID: 35756617
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Sun Y; Li L; Yao W; Liu X; Yang Y; Ma B; Xue D
    Front Genet; 2021; 12():762160. PubMed ID: 34795697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Comprehensive Analyses of Genomic Variations and Assessment of TMB and PD-L1 Expression in Chinese Lung Adenosquamous Carcinoma.
    Cheng Y; Zhang Y; Yuan Y; Wang J; Liu K; Yu B; Xie L; Ou-Yang C; Wu L; Ye X
    Front Genet; 2020; 11():609405. PubMed ID: 33679868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mining The Cancer Genome Atlas database for tumor mutation burden and its clinical implications in gastric cancer.
    Zhao DY; Sun XZ; Yao SK
    World J Gastrointest Oncol; 2021 Jan; 13(1):37-57. PubMed ID: 33510848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.